{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00104091",
      "OrgStudyIdInfo": {
        "OrgStudyId": "IXR-202-22-188"
      },
      "Organization": {
        "OrgFullName": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors",
      "OfficialTitle": "A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection"
    },
    "StatusModule": {
      "StatusVerifiedDate": "May 2011",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2004"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "April 2007",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2007",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "February 22, 2005",
      "StudyFirstSubmitQCDate": "February 22, 2005",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 23, 2005",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "May 20, 2011",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 23, 2011",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyOldNameTitle": "Rivka Kreitman, Ph.D., Vice President, Innovative Research and Development",
        "ResponsiblePartyOldOrganization": "Teva Neuroscience"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Glioblastoma Multiforme"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Gross Total Resection",
          "Convection Enhanced Delivery",
          "Recurrent Glioblastoma Multiforme"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "56",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "1",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "40 mL of TP-38 at a 100 nanograms/mL concentration",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: TP-38"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "TP-38",
            "InterventionDescription": "TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "1"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Evaluate TP-38 at a 100 nanograms/mL concentration for sufficient activity",
            "PrimaryOutcomeTimeFrame": "26 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy parameters including time to progression, safety, and survival",
            "SecondaryOutcomeTimeFrame": "26 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nThe patients must fulfill all the following criteria:\n\nPrevious histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis).\nHistologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous resection (surgical or biopsy) and radiation therapy.\nMedically capable of undergoing the planned surgical gross total resection and the catheter placement.\nAge ≥ 18.\nKarnofsky Performance Status of ≥ 70%.\nLife expectancy of ≥ 3 months.\nPatients must already be taking or begin taking corticosteroids at a stable dose of 4 mg every 6 hours for at least 72 hours prior to catheter placement.\nPatients must be capable of taking, or already taking, anticonvulsant medication.\nPatients must have read, signed, and dated an informed consent according to ICH-GCP, the local regulatory requirement and the rules followed at each institution.\n\nExclusion Criteria:\n\nPatients fulfilling any of the following criteria should not be enrolled in the study:\n\nPrevious myelosuppressive chemotherapy within the past 4 weeks of the start of the infusion. Patients who have received more than two chemotherapy regimens (single therapy or combination therapy) are ineligible.\nAny form of brain radiation within 10 weeks of the start of the infusion.\nPrevious gamma knife radiosurgery, stereotactic radiosurgery, and/or internal radiotherapy, unless the recurrence/progression is histologically confirmed (fine-needle biopsy).\nPrior intracavitary biologic response modifiers or monoclonal antibodies.\nUncontrolled seizures.\nBilateral or multifocal tumors.\nEvidence of cerebral uncal herniation.\nMidline brain shift on MRI scan of > 0.5 cm prior to resection; patients with subfalcine herniation may be enrolled.\nTumors involving the brainstem or cerebellum.\nDiffuse subependymal or CSF disease.\nWomen who are pregnant or breast feeding. All women of child-bearing potential should be excluded unless they have a negative pregnancy test and are using adequate contraceptive measures or are surgically sterile. Post-menopausal women must be amenorrheic for at least 12 months to be considered non-childbearing.\nFertile males not practicing adequate contraception and whose female partners are not using adequate contraceptive protection.\nPrior or concurrent investigational treatment within 30 days of study entry.\nActive infection requiring treatment or having an unexplained febrile illness.\nSystemic diseases or other conditions which may be associated with unacceptable anesthetic/operative risk and/or which would not allow safe completion of this study protocol.\nPrior or concurrent malignancy (curatively treated carcinoma-in-situ or basal cell carcinoma or patients who have been disease free for at least 5 years are eligible).",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022",
      "RemovedCountryList": {
        "RemovedCountry": [
          "Belgium",
          "France",
          "Germany",
          "Italy",
          "Netherlands",
          "United States"
        ]
      }
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000005909",
            "ConditionMeshTerm": "Glioblastoma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001254",
            "ConditionAncestorTerm": "Astrocytoma"
          },
          {
            "ConditionAncestorId": "D000005910",
            "ConditionAncestorTerm": "Glioma"
          },
          {
            "ConditionAncestorId": "D000018302",
            "ConditionAncestorTerm": "Neoplasms, Neuroepithelial"
          },
          {
            "ConditionAncestorId": "D000017599",
            "ConditionAncestorTerm": "Neuroectodermal Tumors"
          },
          {
            "ConditionAncestorId": "D000009373",
            "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009375",
            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
          },
          {
            "ConditionAncestorId": "D000009380",
            "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M14002",
            "ConditionBrowseLeafName": "Recurrence",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4361",
            "ConditionBrowseLeafName": "Brain Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8171",
            "ConditionBrowseLeafName": "Glioblastoma",
            "ConditionBrowseLeafAsFound": "Glioblastoma Multiforme",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3713",
            "ConditionBrowseLeafName": "Astrocytoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8172",
            "ConditionBrowseLeafName": "Glioma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19599",
            "ConditionBrowseLeafName": "Neoplasms, Neuroepithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18997",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19540",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11470",
            "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11472",
            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11477",
            "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2518",
            "ConditionBrowseLeafName": "Glioblastoma",
            "ConditionBrowseLeafAsFound": "Glioblastoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2519",
            "ConditionBrowseLeafName": "Glioma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4092",
            "ConditionBrowseLeafName": "Neuroepithelioma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M11052",
            "InterventionBrowseLeafName": "Mitogens",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}